5243482025-07-012025-09-305243482025-09-305243482025-03-315243482025-04-012025-09-305243482025-07-012025-09-30in-capmkt:OtherExpenses1Member5243482025-04-012025-09-30in-capmkt:OtherExpenses1Member5243482025-07-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15243482025-04-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares524348AARTIDRUGSNOTLISTEDINE767A01016AARTI DRUGS LIMITEDMain BoardEquity2025-04-012026-03-312025-11-072025-10-31INRLakhsQuarterlySecond quarterSingle segmentPharmaceuticals2025-11-0712:00:002025-11-0714:30:00trueCash Flow IndirectNot applicable2025-07-012025-09-30AuditedConsolidated652790000090000065288000003850600000306400000-741000003307000007700000016260000012715000005924700000604100000060410000013620000016300000152500000045160000000004516000000451600000452800000-1191000452800000-1191000912700000104.954.95004.954.951. The above results for the Quarter & Period ended 30th September, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 7th November, 2025. <BR> <BR> 2. As on September 30, 2025 the Company, has 3 (three) subsidiaries, namely, Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited, Pinnacle Chile SpA and 1 (one) step down subsidiary, namely Pharma Go SpA. <BR> <BR> 3. During the chlorosulfonation process at the PTSCL section of the T-150 unit, an incident of HCl gas leakage occurred on September 8, 2025. Pursuant to MPCB directions, the Company has voluntarily suspended the said process as a precautionary measure. The incident has no material or financial impact, and other manufacturing operations at the T-150 unit continue as normal. <BR> <BR> 4. The company has completed the buyback of 6,65,000 equity shares of face value of Rs.10/- representing up to 0.72% of the total number of Equity Shares of the Company at a price of Rs. 900/- per Equity Share (including premium of Rs. 890/- per Equity Share) payable in cash for an aggregate amount of up to Rs. 59,85,00,000/- (excluding filing fees payable to the SEBI, advisors’ fees, stock exchanges fee for usage of their platform for Buyback, transaction costs viz. brokerage, applicable taxes inter alia including Buyback tax, securities transaction tax, GST, stamp duty, public announcement publication expenses, printing and dispatch expenses and other incidental and related expenses etc.)(“Buyback Size”) on September 24, 2024. Post buyback Paid up Share Capital of the Company reduced to Rs. 91,27,00,000 divided into 9,12,70,000 Equity Shares of Rs.10/- each. <BR> <BR> 5. Company has only one business segment i.e. pharmaceuticals. <BR> <BR> 6. The Company’s new manufacturing plant at Sayakha, Gujarat has commenced commercial production/operations w.e.f. September 4, 2025. <BR> <BR> 7. Figures for the previous Quarter have been regrouped or rearranged wherever necessary. <BR> <BR> 8. The aforesaid Audited Financial Results will be uploaded on the Company's website www.aartidrugs.co.in and will also be available on the website of BSE Limited www.bseindia.com and the National Stock Exchange of India Limited www.nseindia.com for the benefit of the shareholders and investors. <BR> <BR> <BR> <BR> FOR AARTI DRUGS LIMITED <BR> <BR> Sd/- <BR> Prakash M. Patil <BR> DIN: 00005618 <BR> (Chairman, Managing Director & CEO) <BR> <BR> <BR> Place: Mumbai <BR> Date: 7th November 20252025-04-012025-09-30AuditedConsolidated124330000004000000124370000007423100000592600000-1989000006387000001627000003098000002393800000113218000001115200000011152000009080000033100000123900000099130000000009913000001100000992400000991900000-568000992900000-5110009127000001010.8610.860010.8610.86Other Expenses1271500000Other Expenses239380000010662600000179140000009910000022540000002200000004454000001299850000047004000000719600000066500000292000004600000149700000744600000075000009703000001312420000026122700000912700000137703000001468300000029000001468590000027356000001400000027496000004330000081540000036083000002976100000735000003694500000376800000023880000069829000008000000004560000078285000001143680000026122700000FOR AARTI DRUGS LIMITED <BR> <BR> Sd/- <BR> Prakash M. Patil <BR> (Chairman, Managing Director&CEO) <BR> DIN: 00005618 <BR> <BR> Place: Mumbai <BR> Date: 7th November 2025028900000669500000000000-788000000000309800000020000000000680000000000000024700000013622000000-162600000-3200000-2100000-100000152360000000000000500000943100000012000000000000000000000320000000-940600000000000002230000006385000000014670000000-562200000208000000208000004580000066600000Foreign currency translation reserve00Foreign currency translation reserve110000011000000001100000